HPRA – Guidance Update HPRA – Guidance Update The Health Products Regulatory Authority (HPRA) has updated some of their guidance documents. Please find the... HPRA – Guidance Update
MHRA Guidance Published – Risk-Adapted Approach to Clinical Trials and Risk Assessments MHRA Guidance Published – Risk-Adapted Approach to Clinical Trials and Risk Assessments The MHRA has published guidance on Risk-Adapted Approach... MHRA Guidance Published – Risk-Adapted Approach to Clinical Trials and Risk Assessments
MHRA Guidance Published – Oversight and Monitoring of Investigational Medical Product Trials MHRA Guidance Published – Oversight and Monitoring of Investigational Medical Product Trials The MHRA has published oversight and monitoring of... MHRA Guidance Published – Oversight and Monitoring of Investigational Medical Product Trials
EU Commission – Public Consultation on REACH Regulation Revision EU Commission – Public Consultation on REACH Regulation Revision The European Commission has launched a public consultation... EU Commission – Public Consultation on REACH Regulation Revision
Webinar on Responsible Manufacturing Effluent Management Technical Guidance Webinar on Responsible Manufacturing Effluent Management Technical Guidance On Friday 18 February 2022 AESGP, EFPIA and Medicines for Europe are... Webinar on Responsible Manufacturing Effluent Management Technical Guidance
EMA Management Board – Minutes from October 2021 Meeting European Medicines Agency (EMA) Management Board Meeting The EMA has published the minutes from its Management Board meeting held on... EMA Management Board – Minutes from October 2021 Meeting
Advisory Council on the Misuse of Drugs – Consumer CBD Products Advisory Council on the Misuse of Drugs – Consumer CBD Products Cannabidiol (CBD) is a non-psychoactive cannabinoid present in the... Advisory Council on the Misuse of Drugs – Consumer CBD Products
MHRA Public Assessment Report – Chloramphenicol Eye Drops Containing Borax and Boric Acid Buffers in Children Under 2 Years MHRA Public Assessment Report – Chloramphenicol Eye Drops Containing Borax and Boric Acid Buffers in Children Under 2 Years MHRA... MHRA Public Assessment Report – Chloramphenicol Eye Drops Containing Borax and Boric Acid Buffers in Children Under 2 Years
MHRA Webinar – Medicines Supply for Northern Ireland MHRA Webinar – Medicines Supply for Northern Ireland Date/Time: Wednesday 2 February 2022, 10:00-11:45 and Thursday 3 February 2022, 14:00-15:45The... MHRA Webinar – Medicines Supply for Northern Ireland
MHRA Consultation on Proposals for Legislative Changes for Clinical Trials MHRA Consultation on Proposals for Legislative Changes for Clinical Trials MHRA has launched a consultation on a set of proposals... MHRA Consultation on Proposals for Legislative Changes for Clinical Trials
MHRA Publishes Marketing Authorisations Granted in December 2021 MHRA’s list of marketing authorisations granted in December 2021 MHRA granted five OTC licences in December 2021. Details of these... MHRA Publishes Marketing Authorisations Granted in December 2021
EMA Public Consultation on “Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics” and EMA Guidance on Companion Diagnostics Consultation Procedure Published EMA Public Consultation on ‘Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified... EMA Public Consultation on “Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics” and EMA Guidance on Companion Diagnostics Consultation Procedure Published
